Columbus Circle Investors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Columbus Circle Investors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-12,437	Closed	-$808K	–	341
2014 Q1	$808K	Sell	12,437 -15,078	-55%	-$1.02M	0.01%	271
2013 Q4	$1.55M	Sell	27,515 -78,705	-74%	-$4.42M	0.01%	263
2013 Q3	$6.51M	Sell	106,220 -5,570	-5%	-$377K	0.05%	239
2013 Q2	$6.53M	Buy	+111,790	New	+$6.88M	0.05%	218

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Columbus Circle Investors's OREX Position: Q2 2014 in Review

Columbus Circle Investors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 12,437 shares — an estimated $808K sold.

Columbus Circle Investors first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $6.53M in Q2 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

Columbus Circle Investors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
Columbus Circle Investors sold 12,437 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $808K.
Columbus Circle Investors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
Columbus Circle Investors's Orexigen Therapeutics, Inc. position peaked at $6.53M in Q2 2013.
129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on Columbus Circle Investors's 13F filing for Q2 2014, filed 31 Jul 2014.